Johnson & Johnson released a report that a single dose of the vaccine has only 66% effectiveness in preventing the Covid-19 pandemic. These data are based on large-scale experiments on three different continents.
In a trial involving 44,000 volunteers, the effectiveness rate in preventing moderate and critical Covid-19 patients in the United States was 72%, 66% in Latin America and only 57% in South Africa, where alarming new variants have spread.
Previously vaccine manufacturers by Pfizer / BioNTech and Moderna Company have announced that the effectiveness of their product vaccines reached around 95% in preventing Covid-19 symptoms when given two doses.
However, the result of that figure is based on experiments conducted in the United States and before the advent of new variants. J&J is now aiming that their vaccines should achieve 85% effectiveness to stop the pandemic from spreading and preventing variant types.
J&J plans to obtain emergency use permission from the U.S. Food and Drug Administration next week.Unlike Pfizer / BioNTech and Moderna vaccines, J&J does not require a second or frozen dose injection. This makes the J&J vaccine one of the top choices.
The Stock Exchange opened lower on Friday after vaccine data from J&J suppressed sentiment and raised institutional and retail market concerns.
Bursah Dow Jones fell 59.5 points, S&P fell 9.3 points and the Nasdaq Exchange fell 52.4 points during the market opening.
